Clinical Trial

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-23; most recent amendment 2025-08-15.
Status change: Not Yet Recruiting → Recruiting 2024-07-17
Trial Details
NCT Number NCT06434597
Lead Sponsor Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Enrollment 60 participants
Start Date 2024-07-17
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-17